Tagged with GE

GE Healthcare There has been much hype about emerging markets, especially those in Asia. How important are these markets for GE and what are your respective goals for the next three years? Every company will tell you that emerging markets are an opportunity, otherwise they would not be called emerging markets. From…

ireland Mr. Mazeman, can you please begin by offering a brief overview of your career to date? I am a French pharmacist by training, with expertise in pharmacology. I have worked for Servier for my entire career. I started in the industry as a medical representative for the company. I went…

Eurogentec Belgium Mr Delwart, you have been acting CEO of EuroGenTec for an impressive 19 years. During your tenure, what would you say has been the single most important change in the business model of the life sciences industry? The pharmaceutical industry is increasingly being under pressure by the rising costs of…

market You established Menarini’s Irish affiliate in 1999. How have you seen the market evolve over these last 13 years? The major changes in the market have principally occurred in the last four or five years, rather than the previous ten. Generally speaking, the industry has always had a very strong…

Department of Health & Ageing You were appointed last year with a specialized portfolio reflecting some of the key priorities on the country’s health care agenda. Would you begin by outlining your mission for your tenure? Prime Minister Gillard announced during the last election in 2010 that both mental health reform and aged care reform…

Boehringer Ingelheim Benelux Can you illustrate to our readers the company’s main milestones and key achievements since you took the reins four years ago? In the last years we have experienced a period of strong growth for the company based on the portfolio which we had. Today, however, following a strong focus on…

TiGenix - Belgium Mr Bravo, in relation to your previous career in big pharma companies, you have recently made a shift into much smaller entities including Cellerix and TiGenix. What motivated you to make such a dramatic and bold shift in your professional life? I was young and ambitious and despite having a…

Amgen Belgium Can you begin by giving us a brief overview of Amgen in Belgium and tell our readers more about the company’s history here? Compared to other, well-established multinationals Amgen is a relatively young biotechnology company with just over 30 years of experience in the industry. Amgen entered the Belgian market…

Generic Medicines Industry Association (GMiA) In trying to be an effective association and positively influence the environment for your members, what have been the main achievements and milestones since you were appointed in 2008? We have been focusing on several strategic priorities over the past four years, firstly on creating a viable commercial environment for…

Biogen Idec Czech Republic Ms. Hrdličková, can you please begin by introducing yourself to our readers, and providing a brief overview of your pharmaceutical career? My educational background is in general and molecular biology, with a specialization in microbiology. I worked for approximately three years doing clinical work in this field at a hospital,…

Amgen Czech Republic Mr. Duc, you first worked in the Czech Republic in 1997, as an Oncology Business Unit manager for Pierre Fabre. The ‘90s in this country have been described to us as a ‘wild’ time, with little regulation and easy growth. Since then, the Czech pharma market became much more complex…

FeBelGen Looking into your background, we see that you’ve spent 8 years at pharma.be, where you were advocating the traditional drug producers. What encouraged you to head FeBelGen since 2006, representing the generic and biosimilar drugs industry in Belgium? When I started to head FeBelGen in 2006, my goal/objective was –…